Despite advancements in sustainability within the medical device and drug delivery sectors, the reliance on virgin, fossil fuel-derived plastics remains a critical concern. This dependency is not only a sustainability issue but also a significant supply chain risk, as disruptions from various global events have highlighted vulnerabilities in the complex supply chains that provide essential polymers. Manufacturers must recognize that the increasing demand for plastics, coupled with declining oil reserves, could lead to unpredictable procurement timelines and potential rationing of materials.
Switching to alternative materials, such as bio-based polymers, presents challenges including higher costs and regulatory hurdles. While some bioplastics are available, their adoption is limited due to concerns over safety and performance. Therefore, manufacturers should focus on circular design principles that prioritize reducing virgin material use and enhancing product longevity. This approach not only addresses sustainability but also strengthens supply chain resilience by minimizing reliance on fragile material sources.
Implementing strategies like reprocessing and remanufacturing can preserve more value compared to traditional recycling methods, which often result in downcycling. As the industry evolves, embracing circularity can provide manufacturers with strategic advantages, allowing them to meet patient needs while mitigating risks associated with volatile supply chains.
Source: contractpharma.com · Image: Atraumatisches Nahtmaterial 17 by Werneuchen, Public domain, via Wikimedia Commons
Open the full market picture for your next decision →
